Shares of Hologic HOLX increased in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share increased 368.85% year over year to $2.86, which beat the estimate of $2.17.
Revenue of $1,610,000,000 up by 89.30% from the same period last year, which beat the estimate of $1,400,000,000.
Guidance
Q2 EPS expected between $2.56 and $2.68.
Q2 revenue expected to be between $1,500,000,000 and $1,560,000,000.
How To Listen To The Conference Call
Date: Jan 27, 2021
Time: 04:30 PM
ET Webcast URL: https://events.globalmeet.com/Public/ClickToJoin/ZW5jPTJHZWIwU3FaRks2Qy9wWWRudFUxUnRzaHl1NW5jVGVodEtGUTJ0WFZJNjRkYTdUUmo3S3c0Zz09
Price Action
52-week high: $81.80
52-week low: $26.49
Price action over last quarter: down 4.12%
Company Description
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: breast health (44% of sales), diagnostics (39%) surgical (14%), and skeletal health (3%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (74%), followed by Europe (12%), Asia (9%), and other international markets (5%). Hologic is headquartered in Bedford, Massachusetts.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.